University of Sydney
Camperdown Campus, Parramatta Road, Sydney, NSW, 2006, Australia
Overview
University of Sydney is an Australian public research university that provides educational services. The university comprises 16 faculties and schools, through which it offers bachelor’s, master’s, and doctoral degrees. Its campuses include Camperdown and Darlington, Cumberland, AGSM, Mallett Street, Orange, Sydney Conservatorium of Music, Rozelle, Camden, Burren Street, and Surry Hills. Its faculties include arts, architecture, agriculture, food and natural resources, economics and business, education and social work, engineering, medicine, pharmacy, science, veterinary science, health sciences, management, law, English teaching, dentistry, transport studies, and international health. University Of Sydney was founded in 1850 and is headquartered in New South Wales, Australia.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 1
- Active investors
- 10
Sector focus
- Education
- Higher Education
- Universities
Investment portfolio
- Baymatob
Participated · Series A · May 2026
Baymatob develops Oli, a wireless, wearable device that monitors maternal and fetal signals and aims to analyse up to fifteen pregnancy and birth conditions and complications. Targeted conditions include postpartum haemorrhage, fetal distress, stillbirth risk and labour progression. The company is conducting pivotal clinical trials across seven sites in Australia and the United States and is advancing regulatory submissions with the TGA and FDA. Baymatob plans to establish manufacturing operations and its headquarters in Australia. Financially, the company has raised $13 million in private capital plus more than $9.5 million in non-dilutive grants and completed a $6.5 million Series A3 in 2025.
- Ferronova
Participated · Series A · May 2020
Ferronova is an Adelaide-based medical technology company developing a super-paramagnetic iron oxide nanoparticle tracer system designed to improve image-guided cancer surgery. The nanoparticles bind to lymph-node cells, allowing surgeons to identify tissue that may harbour metastasised cancer and thereby reduce post-operative recurrence. The company is running a 60-patient, two-year clinical trial on stomach and oesophageal cancers at leading Australian centres, having enrolled 54 patients with completion expected in early 2026. Management plans to extend research to the United States over the next two years as it moves toward regulatory approval and commercial launch. Roughly 1.8 million people are diagnosed with stomach and oesophageal cancers annually, underscoring the market need the firm targets. Ferronova has raised a cumulative $17.5 million in Series A funding, giving it capital to complete trials and pursue commercialisation. Its investor base includes Uniseed/UniSuper, South Australian Venture Capital Fund, Artesian Venture Partners, Renew Pharmaceuticals (UltraGreen.ai), several universities, and health-focused funds. The company’s mission is to enhance surgical precision and improve survival rates in complex, early-stage cancers.